@uroegg @ProtonStorey @seanmmcbride 10-year outcomes of cancer-specific survival for RT vs RP, assuming a skeptical prior, the posterior probability that the true HR < 1 is 56% (in favor of RT) Even higher probability w/ non-informative prior https://t
@rie_ocns_96 内容は⁉️ 因みに 英国ProtecT試験では PSA検査で限局性前立腺がんと診断され ・積極的監視群(545例) ・前立腺摘除術群(553例) ・放射線療法群(545例) での 転移は 積極的監視:51例(9.4%) 前立腺摘除術:26例(4.7%) 放射線療法:27例(5.0%) も予後は変わらなかったんだって https://t.co/oNV2kWUMSk
RT @cancer_K2A: A #prostatecancer treatment decision-making 🧵 1/12 🙍♂️diagnosed with early (localised) #prostatecancer face a tricky choic…
RT @cancer_K2A: A #prostatecancer treatment decision-making 🧵 1/12 🙍♂️diagnosed with early (localised) #prostatecancer face a tricky choic…
RT @cancer_K2A: A #prostatecancer treatment decision-making 🧵 1/12 🙍♂️diagnosed with early (localised) #prostatecancer face a tricky choic…
RT @cancer_K2A: A #prostatecancer treatment decision-making 🧵 1/12 🙍♂️diagnosed with early (localised) #prostatecancer face a tricky choic…
RT @cancer_K2A: A #prostatecancer treatment decision-making 🧵 1/12 🙍♂️diagnosed with early (localised) #prostatecancer face a tricky choic…
RT @cancer_K2A: A #prostatecancer treatment decision-making 🧵 1/12 🙍♂️diagnosed with early (localised) #prostatecancer face a tricky choic…
A #prostatecancer treatment decision-making 🧵 1/12 🙍♂️diagnosed with early (localised) #prostatecancer face a tricky choice between options (active monitoring, radical prostatectomy, radiotherapy) w/ similar effectiveness, but different side effects https
@Wil8769 @jfdwolff @mgtmccartney @BBCr4today There is no difference in age related mortality in those with early screen detected prostate cancer confined to the capsule with 3 treatments ie brachytherapy prostectomy and waitful watching https://t.co/qCoRMw
@Wil8769 @jfdwolff @mgtmccartney @BBCr4today No as there’s no evidence in trials that early treatment affects the all cause age of death see earlier posts with evidence that is replicated world wide eg https://t.co/qCoRMwImAr
RT @GeriSoc: Recommended reading: '10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer' https://t.co/…
RT @GeriSoc: Recommended reading: '10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer' https://t.co/…
RT @GeriSoc: Recommended reading: '10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer' https://t.co/…
Recommended reading: '10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer' https://t.co/ozOCN0CCp0 #BGSconf https://t.co/W7uTaiHClS
@matthew_hobbs @oscdebosc Early diagnosis and three treatments including doing nothing, no difference in mortality https://t.co/oZrqOr2TBF
@dr_coops @neerajaiims @JAMAOnc @OncoAlert @urotoday @Huntsman_GU @cdanicas @GGiannarini @AzadOncology @scserendipity1 @SoaresAndrey @montypal @nsayeghmd @BogdanaSchmidt @ADesaiMD And yes it was unethical IMHO. Enzalutamide monotherapy isn’t even proven to
@robertsherman @ralph_urquhatt @dr_coops @neerajaiims @JAMAOnc @OncoAlert @urotoday @Huntsman_GU @cdanicas @GGiannarini @AzadOncology @scserendipity1 @SoaresAndrey @montypal @nsayeghmd @BogdanaSchmidt @ADesaiMD No data? Yet in your previous tweet you talk
@ARRO_org For prostate: 1. Intact: treatment, surg, or RT? ProtecT: outcomes: https://t.co/GaHvubzeod QOL: https://t.co/W6knhtYqQt 2. Intact: If RT, what fractionation? Phase III trials of SBRT vs hypofrac vs conventional. https://t.co/T7gIXs1TWb Threa
RT @NicholasZaorsky: Low and fav intermediate risk patients are unlikely to die of their disease (<1%). https://t.co/yWyHI8dWoV https://t.c…
RT @NicholasZaorsky: Low and fav intermediate risk patients are unlikely to die of their disease (<1%). https://t.co/yWyHI8dWoV https://t.c…
Low and fav intermediate risk patients are unlikely to die of their disease (<1%). https://t.co/yWyHI8dWoV https://t.co/luBkCWzZKL
RT @NicholasZaorsky: A brief overview: For low and favorable intermediate risk group patients, observation / active surveillance is key!…
A brief overview: For low and favorable intermediate risk group patients, observation / active surveillance is key! These men were eligible for ProtecT, where risk of death from prostate ca was <1%. https://t.co/yWyHI8dWoV https://t.co/TYIQlz7ush
@PCaParker Certainly true--and may be the crux of the question. At 2 years, ~20% of active monitoring patients had received treatment. Unclear what percent of those underwent prostatectomy. @NEJM https://t.co/ayHqOmqgqw https://t.co/XDKhbfZsG6
@AmarUKishan https://t.co/UQxZBXg8v6 Reminder: HR 0.80 (95% CI, 0.22 to 2.99) for the comparison of the radiotherapy group with the surgery group in UK Protect #radonc
@rafaelmet @MZ_GOV_PL Co do raka prostaty, to jest takie ciekawe badanie, z którego wynika, że szanse przeżycia były u chorych takie same, niezależnie od tego, czy poddali się radioterapii, operacji czy nie zastosowali żadnego leczenia interwencyjnego http
RT @DrSpratticus: 3/n 2. Understand the disease. ~0% of pts die of PCa by 5 w/ localized dz. Most deaths are from other things. Studies sh…
Certainly we can all agree no one dies of localized prostate cancer in 5 yrs!
RT @DrSpratticus: 3/n 2. Understand the disease. ~0% of pts die of PCa by 5 w/ localized dz. Most deaths are from other things. Studies sh…
3/n 2. Understand the disease. ~0% of pts die of PCa by 5 w/ localized dz. Most deaths are from other things. Studies showing protons, brachy, RP, etc improve OS by 5 years simply are showing selection bias. It is impossible. https://t.co/OiR1zK382t http
RT @Maherjane: @mattsydes @Rad_Nation Lots of great discussion #radonc #jc sorry not to be available to engage completely but when thinking…
RT @Maherjane: @mattsydes @Rad_Nation Lots of great discussion #radonc #jc sorry not to be available to engage completely but when thinking…
@mattsydes @Rad_Nation Lots of great discussion #radonc #jc sorry not to be available to engage completely but when thinking about prostate cancer survivorship and outcome measurement https://t.co/dyqQuPXr9I this still is essential reading
@subatomicdoc @CJTsaiMDPhD @SprakerMDPhD @fumikochino @ErinGillespieMD @MKnoll_MD @BK_radiation @ARRO_org @ChristinaChapMD @pre_rad @ShaunaRadOnc @_ShankarSiva @TargetingCancer @seanmmcbride True So far cause of death due to neoplasm other than prostate c
RT @MichaelAhdootMD: @JJWUrology @Dr_Geffin It's undeniable that prostate cancer is wildly over treated with 10 yr cancer specific mortalit…
@JJWUrology @Dr_Geffin It's undeniable that prostate cancer is wildly over treated with 10 yr cancer specific mortality under 2% in an the active surveillance arm. I'm confident that with improved diagnosis we can make a dent in this history of over treatm
10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer | NEJM https://t.co/XKGClXKBDO
@dr_vesi @lucascmendez @cancernetwork @DrAndrewLoblaw @DrSpratticus @gerard_morton @kevinmartell @lhscradonc #ProtecTstudy I believe the randomized data. https://t.co/DPC35gQL74
もう古いのかな? .......... 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer | NEJM https://t.co/8nvAJRciOB
RT @subatomicdoc: @WStraza @Rad_Nation In ProtecT the reported QoL in monitoring arm is intent-to-treat. >50% did choose surgery or radiati…
RT @subatomicdoc: @WStraza @Rad_Nation In ProtecT the reported QoL in monitoring arm is intent-to-treat. >50% did choose surgery or radiati…
RT @subatomicdoc: @WStraza @Rad_Nation In ProtecT the reported QoL in monitoring arm is intent-to-treat. >50% did choose surgery or radiati…
RT @subatomicdoc: @WStraza @Rad_Nation In ProtecT the reported QoL in monitoring arm is intent-to-treat. >50% did choose surgery or radiati…
RT @subatomicdoc: @WStraza @Rad_Nation In ProtecT the reported QoL in monitoring arm is intent-to-treat. >50% did choose surgery or radiati…
@WStraza @Rad_Nation In ProtecT the reported QoL in monitoring arm is intent-to-treat. >50% did choose surgery or radiation so the 'observed' decline may be partly due to choice for treatment. https://t.co/PXHd8jEn6M #radonc #jc Anything at #GU20 on t
@PhelanVicky @SIPTU @siptuhealth @RosieCondra I think you meant, for the blue scheme at least, “stupid idea which is more likely to cause harm than good” https://t.co/N9eBrnET4k
@LondonProstate1 @CanesDavid @EricKleinMD @ChapinMD @urogeek @SamiHamid4 Interesting, but does publication of PROTECT 2 years later make this obsolete? https://t.co/8c1qQRAGEr
@sandraturner49 @bogda_koczwara Critical opportunity to help men understand ALL their options, including NO active treatment in some men https://t.co/0SX3zE00py and also to implement modern biomarker-driven registry trials @PCFA @ANZUPtrials https://t.co/8
RT @jazzmanahn: 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer | NEJM https://t.co/YQGj3JRwSa
RT @jazzmanahn: 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer | NEJM https://t.co/YQGj3JRwSa
10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer | NEJM https://t.co/YQGj3JRwSa
@a_dalpra Sure, but citing one (essentially) hypothesis paper and no clinical evidence in prostate cancer that surgery causes cancer to spread. If that were true, then we wouldn’t see indiscernible Kaplan-Meier lines in PROTECT RCT. https://t.co/JVLTNMvrt
RT @JorgeAugustoGaz: El manejo actual para el cáncer de próstata puede realizarse mediante vigilancia activa, cirugía o radioterapia. Estud…
El manejo actual para el cáncer de próstata puede realizarse mediante vigilancia activa, cirugía o radioterapia. Estudio prospectivo comparativo entra las 3 opciones terapéuticas. Resultados completos en https://t.co/NomUKSNa5z https://t.co/0QgPN5BqB8
Cochrane reviews shows vitamin D supplementation alongside standard asthma medication is likely to reduce severe asthmas attacks https://t.co/JsmL5QgUQ8
Cochrane reviews shows vitamin D supplementation alongside standard asthma medication is likely to reduce severe asthma attacks https://t.co/7Ogi3JMTwH
Active monitoring just as effective as surgery or radiotherapy for prostate cancer in terms of survival rate at 10 years - https://t.co/4J2melFHt0
ProtecT Trial 10-year outcomes after management of prostate cancer 1) https://t.co/UK0e43ZE0I 2) https://t.co/2wMfOyQYjP
"10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer" https://t.co/ROkXuJmBMs
RT @IlindelatorreMD: Resultados a 10 años después de la monitorización, cirugía o radioterapia por ca de próstata localizado | NEJM https:/…
Resultados a 10 años después de la monitorización, cirugía o radioterapia por ca de próstata localizado | NEJM https://t.co/Gr5cUmN2JK https://t.co/qAF4JSoA8p
https://t.co/6N8QpgFfEl Monitor, surgery or XRT for localized prostate cancer? No mortality difference at 10 yrs. ProtecT trial
RT @sebasvignoli: Are we witnessing a #medicalreversal in prostate cancer?.It It could be. Remember also ProtecT trial https://t.co/RK2EkRp…
Are we witnessing a #medicalreversal in prostate cancer?.It It could be. Remember also ProtecT trial https://t.co/RK2EkRpYvN
10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer — NEJM https://t.co/VC2cPbVX7P
RT @drtomround: @SamMerriel predicting #prostatecancer progression- references protect paper no diff mortality 10yrs f/u https://t.co/kt4G7…
@SamMerriel predicting #prostatecancer progression- references protect paper no diff mortality 10yrs f/u https://t.co/kt4G7vzLbx #CaPRI2017
Allows me to post my favorite study. Is there any cancer study with a 100% cancer survival? https://t.co/6HftC78VeB @vinay @DoNoHarmProject https://t.co/rszz67yUOM
Allows me to post my favorite study. Is there any cancer study with a 100% cancer survival? @vinay @DoNoHarmProject https://t.co/6HftC78VeB
Excellent study on watchful waiting & choices 4 Prostate cancer https://t.co/lQcSda2DB1 … with PROMs https://t.co/AKYXzbgWsY … https://t.co/aM0VWVo5RC
Excellent study on watchful waiting & choices 4 Prostate cancer https://t.co/lQcSda2DB1 with PROMs https://t.co/AKYXzbgWsY @pash22 https://t.co/6LELrvirRu
RT @DrTPShakespeare: ProtectT RCT data once more supports #radiation therapy over surgery when treating #ProstateCancer @sandraturner49 @Ta…
RT @DrTPShakespeare: ProtectT RCT data once more supports #radiation therapy over surgery when treating #ProstateCancer @sandraturner49 @Ta…
#Prostate Testing for Cancer and Treatment (ProtecT) trial https://t.co/Vv3jgrD9JY : 10 year findings in the @NEJM https://t.co/UYiDHZK1Yg
RT @CSR_Bris: Well done ProtecT Study Group-their paper was shortlisted for BMJ Awards, UK Research Paper 2017. Link to paper - https://t.c…
RT @CSR_Bris: Well done ProtecT Study Group-their paper was shortlisted for BMJ Awards, UK Research Paper 2017. Link to paper - https://t.c…
RT @CSR_Bris: Well done ProtecT Study Group-their paper was shortlisted for BMJ Awards, UK Research Paper 2017. Link to paper - https://t.c…
RT @CSR_Bris: Well done ProtecT Study Group-their paper was shortlisted for BMJ Awards, UK Research Paper 2017. Link to paper - https://t.c…
RT @CSR_Bris: Well done ProtecT Study Group-their paper was shortlisted for BMJ Awards, UK Research Paper 2017. Link to paper - https://t.c…
RT @CSR_Bris: Well done ProtecT Study Group-their paper was shortlisted for BMJ Awards, UK Research Paper 2017. Link to paper - https://t.c…
10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer — NEJM https://t.co/6Zu81ZW7KK
RT @CSR_Bris: Well done ProtecT Study Group-their paper was shortlisted for BMJ Awards, UK Research Paper 2017. Link to paper - https://t.c…
RT @CSR_Bris: Well done ProtecT Study Group-their paper was shortlisted for BMJ Awards, UK Research Paper 2017. Link to paper - https://t.c…
RT @CSR_Bris: Well done ProtecT Study Group-their paper was shortlisted for BMJ Awards, UK Research Paper 2017. Link to paper - https://t.c…
Many of our patients enrolled in this study https://t.co/F7J9E0u90i
RT @CSR_Bris: Well done ProtecT Study Group-their paper was shortlisted for BMJ Awards, UK Research Paper 2017. Link to paper - https://t.c…
RT @CSR_Bris: Well done ProtecT Study Group-their paper was shortlisted for BMJ Awards, UK Research Paper 2017. Link to paper - https://t.c…
RT @CSR_Bris: Well done ProtecT Study Group-their paper was shortlisted for BMJ Awards, UK Research Paper 2017. Link to paper - https://t.c…
RT @CSR_Bris: Well done ProtecT Study Group-their paper was shortlisted for BMJ Awards, UK Research Paper 2017. Link to paper - https://t.c…
Well done ProtecT Study Group-their paper was shortlisted for BMJ Awards, UK Research Paper 2017. Link to paper - https://t.co/X5I8cngPhy https://t.co/BZiGWzaBPh